ERBB2 and breast cancer: In this study, carboplatin AUC5 did not decrease the pCR rate in patients with HER2+ breast cancer who received neoadjuvant TCHP, eliminating the concerns about poorer oncological outcome, in terms of pCR, related to carboplatin dose reduction.